Q-omics provides the consensus-scored MIR1276 profile across patient tissues and cancer cell-line models. MIR1276 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR1276 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, MIR1276 RNA expression shows 7,793 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, STAD, and GBM as cancer lineages where MIR1276 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1276 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1276 survival associations across molecular data types. MIR1276 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1276 RNA expression–survival associations across cancer types. High MIR1276 expression shows unfavorable associations in ACC, STAD, LUSC, KIRC and UCEC, but favorable associations in OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR1276 RNA expression.
This table summarizes MIR1276 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1276. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1276 shows lower tumor expression in STAD and KICH and higher tumor expression in CHOL and LUSC. The STAD box plot shows higher MIR1276 RNA expression in normal versus tumor tissue (log2 FC = −1.255, t-test p = .033).
This table shows molecular features associated with MIR1276 in patient tissues and cancer cell lines. In patient samples, MIR1276 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
